文献
J-GLOBAL ID:202002256903320512
整理番号:20A0127142
EGFR変異を伴う非扁平NSCLCにおけるファーストライン治療としてのペメトレキセドの有無によるゲフィチニブの無作為化第2相試験:最終全生存率とバイオマーカー分析【JST・京大機械翻訳】
A Randomized Phase 2 Study of Gefitinib With or Without Pemetrexed as First-line Treatment in Nonsquamous NSCLC With EGFR Mutation: Final Overall Survival and Biomarker Analysis
著者 (14件):
Yang James Chih-Hsin
(National Taiwan University Hospital, Taipei, Taiwan)
,
Cheng Ying
(Jilin Provincial Cancer Hospital, Changchun, China)
,
Murakami Haruyasu
(Shizuoka Cancer Center, Shizuoka, Japan)
,
Yang Pan-Chyr
(National Taiwan University Hospital, Taipei, Taiwan)
,
He Jianxing
(The First Affiliated Hospital of Guangzhou Medical College, Guangzhou, China)
,
Nakagawa Kazuhiko
(Kindai University Faculty of Medicine, Osaka, Japan)
,
Kang Jin Hyoung
(The Catholic University of Korea, Seoul, Korea)
,
Kim Joo-Hang
(CHA Bundang Medical Center, CHA University, Gyeonggi-do, Korea)
,
Hozak Rebecca R.
(Eli Lilly and Company, Indianapolis, Indiana)
,
Nguyen Tuan Stevon
(Eli Lilly and Company, Indianapolis, Indiana)
,
Zhang Wan Li
(Eli Lilly China, Shanghai, China)
,
Enatsu Sotaro
(Eli Lilly Japan K.K., Kobe, Japan)
,
Puri Tarun
(Eli Lilly and Company, Gurgaon, Haryana, India)
,
Orlando Mauro
(Instituto Alexander Fleming, Buenos Aires, Argentina)
資料名:
Journal of Thoracic Oncology
(Journal of Thoracic Oncology)
巻:
15
号:
1
ページ:
91-100
発行年:
2020年
JST資料番号:
W3145A
ISSN:
1556-0864
資料種別:
逐次刊行物 (A)
記事区分:
原著論文
発行国:
オランダ (NLD)
言語:
英語 (EN)